A Turbo‐Charging System‐Like Contrast Agent for MRI‐Guided STING Pathway‐Activated Cancer Immunotherapy
Advanced Science · 2025
DOI: 10.1002/advs.202410432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Bin Ren und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Engineering, Southern Medical University, 1023 Shatai South Road, Guangzhou, Guangdong, 510515, China. Hauptthemen laut MEDLINE: Contrast Media, Immunotherapy, Magnetic Resonance Imaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Provincial Natural Science Foundation of China, National Natural Science Foundation of China, Guangzhou Key Research and Development Program of China.
Abstract (Originalsprache)
To overcome the problems of Gd‐based contrast agents (GBCAs) (nephrotoxicity and brain deposition) and stimulator of interferon genes (STING) agonists (poor stability, low delivery efficiency, and potential toxicity), in this study, a Turbo‐charging system‐like GBCA is designed and constructed for magnetic resonance imaging (MRI) guided STING pathway‐activated cancer immunotherapy. Poly(acrylic acid) (PAA) is used to coordinate with Gd 3+ , forming a Gd/PAA macrochelate. Both Gd/PAA macrochelate and SR717 are conjugated to cystamine (CA) to obtain SR717‐CA@Gd/PAA self‐assembled nanoparticles (SAN), which are termed as Turbo S because of its similarity with the Turbo‐charging system of cars. After accumulation in tumors and internalization in tumor cells, the disulfide linkage in Turbo S undergoes a cleavage process catalyzed by glutathione (GSH), leading to the release of Gd/PAA and SR717. The released Gd/PAA gain a high r 1 value (17.11 m M −1 s −1 at 7.0 T; 57.81 m M −1 s −1 at 3.0 T), indicating its strong T 1 imaging capability. Turbo S with a low dosage of SR717 (8.9 mg kg −1 ) achieved a higher tumor immunotherapeutic efficacy than free SR717 with a high dosage (30 mg kg −1 ). The excellent delivery efficiency, high tumor treatment efficacy, and superior biosafety demonstrate that the Turbo S can be used as a promising candidate for tumor immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomedical Engineering, Southern Medical University, 1023 Shatai South Road, Guangzhou, Guangdong, 510515, China.
- Department of Breast Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning, 530000, China.
- Medical Imaging Center, Nanfang Hospital, Southern Medical University, 1023 Shatai South Road, Guangzhou, Guangdong, 510515, China.
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, China.
ORCID-Profile: Zheyu Shen
Förderung
- Guangdong Provincial Natural Science Foundation of China
- National Natural Science Foundation of China
- Guangzhou Key Research and Development Program of China
Zitieren
APA
Ren, B., Yan, S., Li, Z., Huang, Y., Cai, H., Yang, J., Fan, Q., Chen, C., Que, F., Wu, G., Huang, L., Zhou, R., Zhu, J., Yan, C., Liu, G., Shen, Z., & Ning, S. (2025). A Turbo‐Charging System‐Like Contrast Agent for MRI‐Guided STING Pathway‐Activated Cancer Immunotherapy. Advanced Science. https://doi.org/10.1002/advs.202410432
Vancouver
Ren B, Yan S, Li Z, Huang Y, Cai H, Yang J, et al. A Turbo‐Charging System‐Like Contrast Agent for MRI‐Guided STING Pathway‐Activated Cancer Immunotherapy. Advanced Science. 2025. doi:10.1002/advs.202410432
BibTeX
@article{Ren2025,
author = {Ren, Bin and Yan, Sihua and Li, Zongheng and Huang, Ya and Cai, Haobin and Yang, Jing and Fan, Qingdeng and Chen, Chunmei and Que, Fanchao and Wu, Guochao and Huang, Lin and Zhou, Ruilong and Zhu, Jiaoyang and Yan, Chenggong and Liu, Gang and Shen, Zheyu and Ning, Shipeng},
title = {A Turbo‐Charging System‐Like Contrast Agent for MRI‐Guided STING Pathway‐Activated Cancer Immunotherapy},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202410432}
}
EUVIMED